STAT3 Cancer Research Results

STAT3, Signal transducer and activator of transcription 3: Click to Expand ⟱
Source:
Type: Oncogene
Stat3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in various cellular processes, including cell growth, survival, differentiation, and immune response.
Stat3 is frequently found to be constitutively activated in many types of cancers, including breast, prostate, lung, and head and neck cancers. (associated with poor prognosis and reduced survival.)

-STAT3 is typically activated by cytokines (such as IL-6) and growth factors binding to their respective receptors.
-Activated STAT3 upregulates the expression of genes that promote cell cycle progression (e.g., cyclin D1) and anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL).
Nor, Normal Healthy: Click to Expand ⟱
Normal Healthy
Scientific Papers found: Click to Expand⟱
1146- AsP,    Potential use of nanoformulated ascorbyl palmitate as a promising anticancer agent: First comparative assessment between nano and free forms
- in-vivo, Nor, NA
TumCCA↑, Apoptosis↑, IL6↓, STAT3↓, angioG↓, TumMeta↓, VEGF↓, MMP9↓, SOD↑, Catalase↑, GSH↓, MDA↓, NO↓, *BioAv↑,
2613- Ba,    Hepatoprotective Effect of Baicalein Against Acetaminophen-Induced Acute Liver Injury in Mice
- in-vivo, Nor, NA
*hepatoP↑, *MDA↓, *SOD↑, *Catalase↑, *GSH↑, *MAPK↓, *p‑JAK2↓, *p‑STAT3↓, *ALAT↓, *AST↓, *ROS↓, *antiOx↑,
1522- Ba,    Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production
- in-vitro, Nor, RAW264.7
*p‑STAT1↓, *p‑STAT3↓, *p‑JAK1↓, *p‑JAK2↓, *iNOS↓, *NO↓, *IL1β↓, *IL6↓, *TNF-α↓, *ROS↓,
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1/CCL2↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27/CDKN1B↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2/KDR/Flk1↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
6136- CHr,  Tras,    Synergistic anticancer effects of Chrysin and trastuzumab in HER2-Positive breast cancer cells
- in-vitro, BC, SkBr3 - in-vitro, BC, BT474 - in-vitro, Nor, MCF10
eff↑, HER2/EBBR2↓, p‑STAT3↓, PD-L1↓, ChemoSen↑,
6342- DRE,    Mechanistic Study on the Inhibitory Effect of Dandelion Extract on Breast Cancer Cell Proliferation and Its Induction of Apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
eff↑, selectivity↑, Apoptosis↑, TumCCA↑, PI3K↓, Akt↓, JAK1↓, STAT↓, PPARγ↑, TumCP↓, SIRT6↓, SCD1↓, STAT3↓, Casp8↓, STAT6↓, PAK1↓, FABP4↓,
6784- EGCG,    Dietary (−)-Epigallocatechin Gallate (EGCG): State-of-the-Art Advances in Bioactivities, Bioavailability Enhancement Strategies, and Applications in Nutrition and Health
- Review, Nor, NA
*antiOx↑, *Inflam↓, *AntiCan↑, *cardioP↑, *neuroP↑, *GutMicro↑, *AntiBio↑, *ROS↓, *TNF-α↓, *IL6↓, TumCP↓, *LDL↓, *NO↓, *Obesity↓, *p‑tau↓, *Aβ↓, *NRF2↑, *SOD↑, *Catalase↑, *GPx↑, *NLRP3↓, *mTOR↓, TumCCA↑, NRF2↓, Apoptosis↑, SIRT1↓, miR-25-5p↓, PARP↑, Casp3↑, Casp9↑, ER Stress↑, TumAuto↑, EMT↓, TumCI↓, TumCMig↓, TGF-β↓, Smad1↓, STAT3↓, VEGF↓, angioG↓, Imm↑, EGFR↓, *GutMicro↑, *Bacteria↓, *AntiViral↑, *BioAv↓, *BioAv↑, *eff↑, *BioAv↑, eff↑, ChemoSen↑, *toxicity↝,
6814- EMD,    Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics
- Review, Nor, NA
AntiCan↑, *hepatoP↑, *Inflam↑, *antiOx↑, *AntiBio↑, *BioAv↓, *AntiViral↑, *AntiDiabetic↑, *neuroP↑, CSCs↓, NOTCH↓, β-catenin/ZEB1↓, STAT3↓, TumCCA↑, *TNF-α↓, IL6↓, IL1β↓, *MMP9↓, *HO-1↑, cMyc↓, Mcl-1↓,
6819- EMD,    Recent advances in the therapeutic potential of emodin for human health
- Review, Nor, NA
AntiCan↑, *AntiDiabetic↑, *neuroP↑, *Inflam↓, *antiOx↑, *BioAv↓, *BioAv↑, *SOD↑, *GPx↑, *GSH↑, *NRF2↑, *ROS↓, *lipid-P↓, *Cyt‑c↓, *BAX↓, *Bcl-2↓, *iNOS↓, *NO↓, *IL6↓, *IL10↓, *IL17↓, *IFN-γ↓, *NF-kB↓, *LC3II↓, *Akt↓, *Beclin-1↓, *AMPK↓, *TNF-α↓, *PGE2↓, *Apoptosis↓, *Casp3↓, *Casp9↓, *P53↓, *P21↓, *NAD↓, *ATP↓, *CHOP/DDIT3↓, *GADD34↓, *ATF4↓, tumCV↓, Apoptosis↑, TumCG↓, TumCI↓, TumMeta↓, CSCs↓, NOTCH1↓, STAT3↓, eff↑, miR-34a↓, *neuroP↑, *BDNF↓, *hepatoP↑, *ALAT↓, *AST↓, TG/TAG↓, ROS↑, Slug↓, EMT↓, Glycolysis↓, ChemoSen↑, P-gp↓, Ki-67↓, PCNA↓, ER Stress↑, TRIB3↑, NF-kB↑, TumMeta↑, *Imm↓, *toxicity↝,
6836- EMD,    Emodin and the Anthraquinone Scaffold: Therapeutic Promise and Strategies to Overcome Translational Barriers
- Review, Nor, NA
*antiOx↑, *neuroP↑, *Inflam↓, *hepatoP↑, AntiTum↑, *Bacteria↓, *diuretic↑, *AntiDiabetic↑, *BioAv↝, *NF-kB↓, *AMPK↑, *JAK↓, *STAT3↓, *ROS↓, *lipid-P↓, ROS↑, TumCCA↑, CycB/CCNB1↓, BAX↑, Bcl-2↓, MOMP↑, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, Apoptosis↑, P53↑,
7084- GAR,    A unique in vivo pharmacokinetic profile, in vitro metabolic stability and hepatic first-pass metabolism of garcinol, a promising novel anticancer phytoconstituent, by liquid chromatography–mass spectrometry
- in-vivo, Nor, NA
*BioAv↝, *Dose↝, *Inflam↓, *antiOx↑, *chemoPv↑, Wnt↓, β-catenin/ZEB1↓, ERK↓, PI3K↓, Akt↓, NF-kB↓, STAT3↓, TumCP↓, antiNeop↑, ChemoSen↑, chemoP↑,
7245- Gink,    Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity
- vitro+vivo, Pca, DU145 - in-vitro, CRC, HCT116 - in-vitro, Nor, MCF10
STAT3↓, cycD1/CCND1↓, survivin↓, Bcl-2↓, Bcl-xL↓, TumCG↓, Dose↝, TumCCA↑, Apoptosis↑, TumVol↓, TumW↓,
7542- HT,    Hydroxytyrosol Induces Apoptosis and Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B - in-vitro, Nor, RWPE-1
TumCP↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, CDK2↓, CDK4↓, Apoptosis↑, Casp↑, cl‑PARP↑, Bax:Bcl2↑, tumCV↓, Akt↓, STAT3↓, NF-kB↓, AR↓, ROS↑, mtDam↑, BioAv↓, toxicity↓, eff↑,
2925- LT,    Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3
- in-vitro, Cerv, HeLa - in-vitro, Nor, HEK293 - in-vitro, BC, MCF7
HSP90↓, p‑STAT3↓, Apoptosis↑, selectivity↑,
2921- LT,    Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies
- Review, Nor, NA
*hepatoP↑, *AMPK↑, *SIRT1↑, *ROS↓, STAT3↓, TNF-α↓, NF-kB↓, *IL2↓, *IFN-γ↓, *GSH↑, *SREBP1↓, *ZO-1↑, *TLR4↓, BAX↑, Bcl-2↓, XIAP↓, Fas↑, Casp8↑, Beclin-1↑, *TXNIP↓, *Casp1↓, *IL1β↓, *IL18↓, *NLRP3↓, *MDA↓, *SOD↑, *NRF2↑, *ER Stress↓, *ALAT↓, *AST↓, *iNOS↓, *IL6↓, *HO-1↑, *NQO1↑, *PPARα↑, *ATF4↓, *CHOP/DDIT3↓, *Inflam↓, *antiOx↑, *GutMicro↑,
533- MF,    Effects of extremely low-frequency magnetic fields on human MDA-MB-231 breast cancer cells: proteomic characterization
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumCD↑, necrosis↑, mt-ROS↑, other↑, *STAT3↓, STAT3↑,
5155- PTL,    Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases
- in-vitro, Liver, HepG2 - in-vitro, Nor, MEF - in-vitro, Cerv, HeLa - in-vitro, BC, MDA-MB-453
JAK↓, ROS↑, TumCMig↓, TumCG↓, STAT3↓,

Showing Research Papers: 1 to 17 of 17

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 17

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   GSH↓, 1,   MDA↓, 1,   NRF2↓, 1,   ROS↑, 5,   mt-ROS↑, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   MEK↓, 1,   MMP↓, 1,   mtDam↑, 1,   Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cMyc↓, 1,   FABP4↓, 1,   Glycolysis↓, 2,   PPARγ↑, 1,   p‑S6K↓, 1,   SCD1↓, 1,   SIRT1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 4,   Apoptosis↑, 8,   BAX↑, 2,   Bax:Bcl2↑, 2,   Bcl-2↓, 4,   Bcl-xL↓, 1,   Casp↑, 1,   Casp3↑, 3,   Casp7↑, 1,   Casp8↓, 1,   Casp8↑, 1,   Casp9↑, 3,   Cyt‑c↑, 1,   Fas↑, 1,   Mcl-1↓, 1,   MOMP↑, 1,   necrosis↑, 1,   p27/CDKN1B↑, 1,   survivin↓, 1,   Telomerase↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,   miR-25-5p↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,   tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 2,   HSP90↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 1,   PARP↑, 1,   cl‑PARP↑, 1,   PCNA↓, 1,   SIRT6↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 2,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 3,   cycE/CCNE↓, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 1,   CSCs↓, 3,   Diff↓, 1,   EMT↓, 3,   ERK↓, 2,   miR-34a↓, 1,   p‑mTORC1↓, 1,   n-MYC↓, 1,   Nestin↓, 1,   NOTCH↓, 2,   NOTCH1↓, 1,   PI3K↓, 3,   PTEN↑, 1,   SOX2↓, 1,   STAT↓, 1,   STAT3↓, 11,   STAT3↑, 1,   p‑STAT3↓, 2,   STAT6↓, 1,   TumCG↓, 3,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

Ki-67↓, 1,   MMP2↓, 1,   MMP9↓, 2,   PAK1↓, 1,   Slug↓, 1,   Smad1↓, 1,   TGF-β↓, 1,   TRIB3↑, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 4,   TumMeta↓, 2,   TumMeta↑, 1,   uPA↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   EGFR↓, 2,   Hif1a↓, 1,   NO↓, 1,   VEGF↓, 3,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CCR7↓, 1,   COX2↓, 1,   CXCR4↓, 1,   IL1β↓, 1,   IL6↓, 3,   Imm↑, 1,   Inflam↓, 1,   JAK↓, 1,   JAK1↓, 1,   JAK2↓, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 3,   NF-kB↑, 1,   PD-L1↓, 1,   PGE2↓, 2,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   ChemoSen↑, 5,   Dose?, 1,   Dose↓, 1,   Dose↑, 1,   Dose↝, 1,   eff↑, 8,   eff↝, 1,   RadioS↑, 1,   selectivity↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   EGFR↓, 2,   HER2/EBBR2↓, 1,   IL6↓, 3,   Ki-67↓, 1,   PD-L1↓, 1,   TG/TAG↓, 1,   TRIB3↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   antiNeop↑, 1,   AntiTum↑, 1,   chemoP↑, 1,   toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 147

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 2,   diuretic↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 7,   Catalase↑, 2,   GPx↑, 2,   GSH↑, 3,   HO-1↑, 2,   lipid-P↓, 2,   MDA↓, 2,   NQO1↑, 1,   NRF2↑, 3,   ROS↓, 6,   SOD↑, 4,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 3,   AMPK↓, 1,   AMPK↑, 2,   LDL↓, 1,   NAD↓, 1,   PPARα↑, 1,   SIRT1↑, 1,   SREBP1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↓, 1,   BAX↓, 1,   Bcl-2↓, 1,   Casp1↓, 1,   Casp3↓, 1,   Casp9↓, 1,   Cyt‑c↓, 1,   GADD34↓, 1,   iNOS↓, 3,   MAPK↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 2,   ER Stress↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↓, 1,   LC3II↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

mTOR↓, 1,   p‑STAT1↓, 1,   STAT3↓, 2,   p‑STAT3↓, 2,  

Migration(tgid=13) ⓘ

MMP9↓, 1,   TXNIP↓, 1,   ZO-1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

ATF4↓, 2,   NO↓, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IFN-γ↓, 2,   IL10↓, 1,   IL17↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL2↓, 1,   IL6↓, 4,   Imm↓, 1,   Inflam↓, 5,   Inflam↑, 1,   JAK↓, 1,   p‑JAK1↓, 1,   p‑JAK2↓, 2,   NF-kB↓, 2,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 4,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↓, 1,   p‑tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   NLRP3↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 4,   BioAv↝, 2,   Dose↝, 1,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 3,   AST↓, 3,   GutMicro↑, 3,   IL6↓, 4,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 3,   cardioP↑, 1,   chemoPv↑, 1,   hepatoP↑, 5,   neuroP↑, 5,   Obesity↓, 1,   toxicity↝, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 2,   Bacteria↓, 2,  
Total Targets: 88

Scientific Paper Hit Count for: STAT3, Signal transducer and activator of transcription 3
3 Emodin
2 Baicalein
2 Luteolin
1 Ascorbyl Palmitate
1 Berberine
1 Chrysin
1 Trastuzumab
1 Dandelion Root
1 EGCG (Epigallocatechin Gallate)
1 Garcinol
1 Ginkgetin
1 HydroxyTyrosol
1 Magnetic Fields
1 Parthenolide
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:49  Cells:%  prod#:%  Target#:373  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page